Core Insights - Pyxis Oncology has completed target enrollment in the Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) for 2L+ recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in Q1 2026, with updated data expected mid-2026 [1][5] - The company has appointed Thomas Civik as Interim Chief Executive Officer, focusing on clinical execution and operations to deliver robust datasets [3][6] - Financial results for the year ended December 31, 2025, show revenues of $13.9 million, a decrease from $16.1 million in 2024, with a net loss of $79.6 million [8][10] Clinical Development Updates - The Phase 1 monotherapy study of MICVO in 2L+ R/M HNSCC reported a 46% confirmed objective response rate (ORR) and a 92% disease control rate (DCR) [4] - In combination with KEYTRUDA, MICVO showed a 71% confirmed ORR and a 100% DCR in 1L/2L+ R/M HNSCC [4] - The ongoing studies are designed to evaluate the impact of modified weight-based dosing on safety and efficacy, with results anticipated in mid-2026 [7][11] Financial Performance - Total revenues for 2025 were $13.9 million, down from $16.1 million in 2024, primarily due to changes in milestone revenues and royalty rights [10][15] - Research and development expenses increased to $73.7 million in 2025 from $58.7 million in 2024, attributed to higher clinical trial costs [10][16] - The company reported a net loss of $79.6 million for 2025, slightly higher than the $77.3 million loss in 2024 [10][16] Leadership and Corporate Updates - Thomas Civik was appointed as Interim CEO in February 2026, bringing extensive experience in advancing cancer therapeutics [6][10] - Heather Knowles joined as Senior Vice President, Head of Global Clinical Operations, enhancing the company's clinical development capabilities [10] - The company has also appointed Alex Kane as Senior Vice President, Investor Relations and Capital Markets, to strengthen investor engagement [10] Pipeline and Future Outlook - Pyxis Oncology expects to report updated data from the ongoing MICVO Phase 1/2 combination study with KEYTRUDA in the second half of 2026 [7][11] - The company has received Fast Track Designation from the FDA for MICVO in treating adult patients with R/M HNSCC [12]

Core Viewpoint - Pyxis Oncology, Inc. is undergoing a leadership transition with the appointment of Thomas Civik as Interim CEO, following the departure of Lara S. Sullivan, to ensure continuity in advancing the company's strategic and clinical goals [1][2][3]. Leadership Transition - Thomas Civik, a long-time member of the Board of Directors and an experienced biotechnology executive, has been appointed as Interim Chief Executive Officer [2][4]. - Lara S. Sullivan has stepped down from her roles as President, CEO, and Chief Medical Officer after six years of leadership [2][4]. - The Board of Directors is conducting a structured search for a permanent CEO while maintaining operational continuity through the established clinical development leadership team [3][4]. Company Focus and Clinical Programs - Pyxis Oncology's lead program, micvotabart pelidotin (MICVO), is currently in a Phase 1 monotherapy study for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) and a Phase 1/2 study in combination with Merck's pembrolizumab [4][8]. - The company aims to prioritize the execution of its clinical programs and upcoming milestones, focusing on improving patient outcomes in difficult-to-treat cancers [5][8]. Background of Interim CEO - Thomas Civik previously served as President and CEO of Five Prime Therapeutics, leading its acquisition by Amgen for $1.9 billion in April 2021 [5][6]. - He has extensive experience in oncology development, having held leadership roles at Genentech for 17 years, overseeing key therapies such as Avastin and Tecentriq [6]. About Pyxis Oncology - Pyxis Oncology is a clinical-stage biopharmaceutical company focused on developing therapeutics for difficult-to-treat cancers, with MICVO being a first-in-concept antibody-drug conjugate targeting extradomain-B of fibronectin [7][10]. - MICVO is designed to treat solid tumors through a multi-pronged mechanism of action, including direct tumor cell killing and mobilizing an anti-tumor immune response [10].

Core Insights - Pyxis Oncology Inc. has released preliminary data from its ongoing Phase 1 studies of micvotabart pelidotin (MICVO) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) [1][5] Group 1: Study Results - In the monotherapy cohort, the confirmed overall response rate was 46% (6 of 13 patients), with a disease control rate of 92% (12 of 13 patients) [3] - The combination therapy cohort showed a confirmed overall response rate of 71% (5 of 7 patients) and a disease control rate of 100% (7 of 7 patients) [4] Group 2: Tolerability and Safety - MICVO was generally well tolerated, with no Grade 4 or Grade 5 treatment-related adverse events reported [4] - There was a noted 28% discontinuation rate in the study, which is significantly higher than the typical 10%-15% seen in oncology trials [7] Group 3: Future Plans - Pyxis Oncology plans to present updated data from the Phase 1 monotherapy study in mid-2026 and from the Phase 1/2 study in the second half of 2026 [5] - The company is evaluating the path forward for pivotal studies of MICVO as both a monotherapy and in combination with pembrolizumab [5] Group 4: Financial Update - Pyxis Oncology completed the sale of its rights to royalties from the commercialization of Enzeshu for a one-time cash payment of $11 million, which will support the development of MICVO [6] - The current cash runway is expected to fund operations through data milestones and into the fourth quarter of 2026 [6] Group 5: Market Reaction - Following the data release, Pyxis Oncology shares closed down about 49% at $1.73, reflecting concerns over limited data interpretability and tolerability issues [7] - Analysts have reiterated a Market Perform rating on Pyxis shares due to uncertainties regarding efficacy and the small sample size of the studies [9]

MICVO Monotherapy Efficacy - MICVO monotherapy demonstrated a validated efficacy signal in 2L+ R/M HNSCC, with a 46% confirmed ORR and a 92% DCR (n=13, 5.4 mg/kg)[4] - In the Phase 1 monotherapy dose expansion study at 5.4 mg/kg, Arm 1 (post-PD1/post-Platinum) showed a 60% confirmed ORR (N=5)[32] - Arm 2 (post-PD1/post-EGFRi) in the monotherapy study showed a 25% confirmed ORR (N=4), exceeding the PI benchmark of 20%+[32] - MICVO monotherapy at 5.4 mg/kg demonstrated clear activity with deep responses and exceptional disease control[35] MICVO + KEYTRUDA® Combination Efficacy - MICVO combined with KEYTRUDA® showed a promising emerging efficacy profile in 1L/2L+ R/M HNSCC, with a 71% confirmed ORR and 100% DCR (n=7, 3.6 mg/kg & 4.4 mg/kg)[4] MICVO Safety and Tolerability - MICVO at 5.4 mg/kg in R/M HNSCC showed no Grade 4 or Grade 5 ADC payload TRAEs of interest[40] - Initial data supports a lack of overlapping toxicities observed between MICVO and KEYTRUDA®[52] Market and Clinical Development - FDA aligned on a 2L+ monotherapy pivotal trial design for MICVO[4] - The US R/M HNSCC market is large, growing, and relatively uncrowded, making it ripe for innovation[17] - Projected 2029 US market data shows a significant number of drug-treatable patients, with ~31K in 1L, ~21K in 2L, and ~8K in 3L[18]

Core Insights - Pyxis Oncology announced positive preliminary data from Phase 1 clinical studies of micvotabart pelidotin (MICVO), an antibody-drug conjugate targeting extradomain-B of fibronectin, in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) [1][2] Monotherapy Findings - In the Phase 1 monotherapy study, MICVO demonstrated a 46% confirmed objective response rate (ORR) and a 92% disease control rate (DCR) at a dose of 5.4 mg/kg in 2L+ R/M HNSCC [4] - The study included 18 patients, all of whom had prior systemic therapy, with a median of 3 prior lines of therapy [5] Combination Therapy Findings - In the Phase 1/2 study combining MICVO with pembrolizumab, the confirmed ORR was 71% and the DCR was 100% at doses of 3.6 mg/kg and 4.4 mg/kg [4][8] - The combination therapy included patients with varying PD(L)-1 CPS scores, and responses were observed even in those who had previously progressed on checkpoint inhibitors [8] Future Developments - Updated data from the ongoing Phase 1 monotherapy study is expected in mid-2026, while updated data from the combination study is anticipated in the second half of 2026 [9] - The company has received FDA alignment on the clinical trial design for a pivotal monotherapy study in 2L+ R/M HNSCC and is evaluating the path forward for pivotal studies [10] Financial Update - Pyxis Oncology completed the sale of rights to royalties from the commercialization of Enzeshu for a one-time cash payment of $11 million, which will support the development of MICVO [11]

Core Insights - Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for difficult-to-treat cancers [2] - The company will participate in two upcoming investor conferences in November 2025, including the Guggenheim 2 Annual Healthcare Innovation Conference and the Stifel 2025 Healthcare Conference [1][3] Company Overview - Pyxis Oncology's lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody drug conjugate (ADC) targeting extradomain-B of fibronectin (EDB+FN), which is overexpressed in various solid tumors [2] - MICVO aims to treat solid tumors through a mechanism involving direct tumor cell killing, bystander effect, and immunogenic cell death [2] - The drug is currently in Phase 1 clinical studies for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and other solid tumors, both as a monotherapy and in combination with Merck's KEYTRUDA® [2]

Core Insights - Pyxis Oncology is advancing its lead candidate, micvotabart pelidotin (MICVO), targeting recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) with preliminary data expected in Q4 2025 [1][5] Pipeline & Clinical Updates - Ongoing Phase 1 clinical studies of MICVO include monotherapy and combination approaches, with a focus on 2L/3L R/M HNSCC patients and a collaboration with Merck for combination therapy with KEYTRUDA® [4][5] - Preliminary data from the Phase 1 monotherapy dose expansion study and the Phase 1/2 combination dose escalation study will be presented, highlighting MICVO's unique mechanism of action and its potential to improve treatment outcomes [4][5] - Recent translational data presented at ESMO 2025 and AACR-NCI-EORTC provided insights into MICVO's pharmacodynamics and its effects on tumor microenvironment remodeling and immune activation [4][5] Financial Results - As of September 30, 2025, Pyxis Oncology reported cash and cash equivalents of $77.7 million, sufficient to fund operations into the second half of 2026 [11] - Research and development expenses for Q3 2025 were $17.8 million, slightly up from $17.7 million in Q3 2024, with a notable increase in MICVO program-specific costs [11] - The net loss for Q3 2025 was $22.0 million, consistent with the previous year, reflecting ongoing investment in clinical development [11][14]

Core Insights - Pyxis Oncology is advancing micvotabart pelidotin (MICVO), a first-in-concept antibody-drug conjugate (ADC) targeting extradomain-B of fibronectin, with promising translational data to be presented at ESMO 2025 and AACR-NCI-EORTC conferences [1][2][10] Mechanism of Action - MICVO operates through a three-pronged mechanism: direct tumor cell killing, bystander effect, and immunogenic cell death, which contributes to its potential effectiveness against solid tumors [1][2][12] - The ADC's unique extracellular-cleaving mechanism distinguishes it from traditional ADCs that target cell surfaces and internalize [2][12] Clinical Development - Ongoing clinical studies focus on head and neck squamous cell carcinoma (HNSCC), with a Phase 1/2 combination study of MICVO and pembrolizumab initiated for recurrent and metastatic cases [10][13] - Data from 37 clinical samples indicate a reduction in circulating tumor DNA tumor fraction after treatment with MICVO, particularly at a dose of 5.4 mg/kg, supporting its development in HNSCC [2][10] Presentation Details - At ESMO 2025, two posters will present histological biomarker analysis and longitudinal changes in circulating tumor DNA from the Phase 1 dose escalation study [4][5] - Six additional posters at the AACR-NCI-EORTC conference will further explore MICVO's mechanism of action and its impact on tumor microenvironment remodeling [5][6] Future Directions - The company aims to continue developing MICVO based on the positive signals observed in HNSCC and its potential as both a monotherapy and in combination with anti-PD1 therapy [2][10]

Core Insights - Pyxis Oncology, Inc. has appointed Alex Kane as Senior Vice President of Investor Relations & Capital Markets, effective immediately [1] - Kane has 20 years of experience in investor relations and capital markets, particularly in the life sciences sector [2] - His previous roles include Vice President at Guggenheim Securities and senior positions at Praxis Precision Medicines and PTC Therapeutics, where he managed IPOs and investor engagement [3] Company Overview - Pyxis Oncology is a clinical-stage company focused on developing antibody-drug conjugate (ADC) therapeutics for challenging cancers [1] - The lead candidate, micvotabart pelidotin (MICVO), is currently in Phase 1 clinical studies targeting recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) [5] - The company has initiated a Phase 1/2 combination study of MICVO with Merck's KEYTRUDA® in patients with R/M HNSCC and other advanced solid tumors [5]

Core Insights - Pyxis Oncology is making significant progress in its Phase 1 clinical trials for micvotabart pelidotin (MICVO), targeting recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) with preliminary data expected in the second half of 2025 and first half of 2026 [1][6] - The company has a cash runway that is expected to last through data milestones and into the second half of 2026, with cash and cash equivalents totaling $90.4 million as of June 30, 2025 [1][6] Pipeline Updates - The Phase 1/2 combination study of MICVO and KEYTRUDA® (pembrolizumab) is progressing well, with preliminary data anticipated in the second half of 2025 [5][6] - Preliminary data from the Part 2 monotherapy expansion cohorts of the ongoing Phase 1 clinical trial for R/M HNSCC patients is expected in the second half of 2025, with additional data from patients who have received prior EGFRi and PD-1 inhibitor therapy anticipated in the first half of 2026 [6] Financial Results - For the quarter ended June 30, 2025, Pyxis Oncology reported revenues of $2.8 million, a significant increase from $0 in the same quarter of 2024, primarily due to milestone revenue from the approval of suvemcitug in China [6][10] - Research and development expenses increased to $17.1 million for the quarter ended June 30, 2025, compared to $14.0 million for the same period in 2024, driven by increased manufacturing and clinical trial-related expenses [10] - The net loss for the quarter was $18.4 million, or ($0.30) per common share, compared to a net loss of $17.3 million, or ($0.29) per common share, for the same quarter in 2024 [10][12]